Serum, Cell-Free, HPV-Human DNA Junction Detection and HPV Typing for Predicting and Monitoring Cervical Cancer...

Area of Science:

• Oncology
• Virology
• Genetics

Background:

• Cervical cancer is primarily caused by human papillomaviruses (HPVs), with viral DNA often integrating into the host genome.
• Identifying biomarkers for predicting recurrence and monitoring treatment is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the utility of detecting tumor-specific HPV-human DNA junctions in serum cell-free DNA (cfDNA) for predicting cervical cancer recurrence.
• To assess the association between HPV phylogenetic clade and cancer recurrence risk.

Main Methods:

• Analysis of tumor-specific HPV-human DNA junctions in serum cfDNA from cervical cancer patients at diagnosis and six months post-treatment.
• Retrospective analysis correlating junction detectability with cancer recurrence.
• Determination of HPV types in tumor tissue and comparison with recurrence rates using The Cancer Genome Atlas (TCGA) database.

Main Results:

• HPV-human DNA junctions were detectable in serum cfDNA of a subset of cervical cancer patients.
• Higher detectability of these junctions was associated with increased risk of cancer recurrence.
• Cervical cancers caused by non-α9 HPV types exhibited higher recurrence frequencies compared to α9 types.

Conclusions:

• Detection of HPV-human DNA junctions in serum cfDNA, alongside HPV typing, can aid in predicting cervical cancer recurrence risk.
• Serum cfDNA screening for these junctions offers a potential non-invasive method for monitoring treatment response and detecting recurrence.